<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">31098</article-id><article-id pub-id-type="doi">10.7554/eLife.31098</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Targeting RAS driven human cancer cells with antibodies to upregulated and essential cell-surface proteins</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-94585"><name><surname>Martinko</surname><given-names>Alexander John</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4025-959X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96229"><name><surname>Truillet</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-6531"><name><surname>Julien</surname><given-names>Olivier</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7068-7299</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96230"><name><surname>Diaz</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45857"><name><surname>Horlbeck</surname><given-names>Max A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3875-871X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96231"><name><surname>Whiteley</surname><given-names>Gordon</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96232"><name><surname>Blonder</surname><given-names>Josip</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30197"><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2445-670X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96233"><name><surname>Bandyopadhyay</surname><given-names>Sourav</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3120-923X</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-77476"><name><surname>Evans</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6510"><name><surname>Wells</surname><given-names>James A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8267-5519</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmaceutical Chemistry</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Radiology and Biomedical Imaging</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Cancer Research Technology Program</institution>, <institution>Frederick National Laboratory for Cancer Research</institution>, <addr-line><named-content content-type="city">Frederick</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Diller Family Comprehensive Cancer Center</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-52143"><name><surname>Settleman</surname><given-names>Jeffrey</given-names></name><role>Reviewing editor</role><aff><institution>Calico Life Sciences</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jim.wells@ucsf.edu</email> (JW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>01</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e31098</elocation-id><history><date date-type="received"><day>09</day><month>08</month><year>2017</year></date><date date-type="accepted"><day>04</day><month>01</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Martinko et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Martinko et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-31098-v1.pdf"/><abstract><p>While there have been tremendous efforts to target oncogenic RAS signaling from inside the cell, little effort has focused on the cell-surface. Here, we used quantitative surface proteomics to reveal a signature of proteins that are upregulated on cells transformed with KRAS<sup>G12V</sup>, and driven by MAPK pathway signaling. We next generated a toolkit of recombinant antibodies to seven of these RAS induced proteins. We found that five of these proteins are broadly distributed on cancer cell lines harboring RAS mutations. In parallel, a cell-surface CRISPRi screen identified integrin and Wnt signaling proteins as critical to RAS transformed cells. We show that antibodies targeting CDCP1, a protein common to our proteomics and CRISPRi datasets, can be leveraged to deliver cytotoxic and immunotherapeutic payloads to RAS transformed cancer cells and report for RAS signaling status <italic>in vivo</italic>. Taken together, this work presents a technological platform for attacking RAS from outside the cell.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA191018</award-id><principal-award-recipient><name><surname>Martinko</surname><given-names>Alexander John</given-names></name><name><surname>Julien</surname><given-names>Olivier</given-names></name><name><surname>Wells</surname><given-names>James A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source><award-id>GM097316</award-id><principal-award-recipient><name><surname>Martinko</surname><given-names>Alexander John</given-names></name><name><surname>Wells</surname><given-names>James A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM097316</award-id><principal-award-recipient><name><surname>Martinko</surname><given-names>Alexander John</given-names></name><name><surname>Julien</surname><given-names>Olivier</given-names></name><name><surname>Wells</surname><given-names>James A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>James A Wells, Celgene Corp provided some of the funding for this work.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN110806-03C) of the University of California San Francisco. Animals that were studied with PET/CT were anesthitized with a mixture of isoflurane/oxygen and humanely euthanized with CO2(g).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="datasets"><title>Major datasets</title><p/><p>The following previously published datasets were used:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="https://www.gtexportal.org/home/" source-id-type="uri"><collab>GTEx Consortium</collab>, <year>2013</year><x>,</x> <source>The Genotype-Tissue Expression (GTEx) project</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="https://www.gtexportal.org/home/">https://www.gtexportal.org/home/</ext-link><x>,</x> <comment>phs000424.vN.pN</comment></related-object><related-object content-type="generated-dataset" id="dataro2" source-id="http://www.cbioportal.org/study?id=paad_tcga#mutations" source-id-type="uri"><collab>NCI-CGA</collab>, <year>2017</year><x>,</x> <source>The Cancer Genome Atlas ( Pancreatic Adenocarcinoma)</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/study?id=paad_tcga#mutations">http://www.cbioportal.org/study?id=paad_tcga#mutations</ext-link><x>,</x> <comment>N/A</comment></related-object></p></sec><supplementary-material><ext-link xlink:href="elife-31098-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>